Case report highlights recurrent CMV retinitis in a patient undergoing daratumumab therapy, suggesting the need for careful monitoring.
CMV retinitis is a rare but serious complication in patients undergoing daratumumab-based therapy. This case highlights the importance of ophthalmologic surveillance and flexible treatment strategies in immunocompromised patients unable to tolerate full-dose systemic antiviral agents.
No takes yet. Share an insight, caveat, or question.
Deistler et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: